{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:14:31Z","timestamp":1794482071799,"version":"4.9.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Treatment-free remission (TFR) is a major therapeutic goal in chronic myeloid leukemia. This study analyzed 5-year follow-up data and immune profiling from 2 independent phase 2 trials conducted by the Japan Adult Leukemia Study Group (JALSG), N-STOP216 (nilotinib [NIL], n = 51) and D-STOP216 (dasatinib [DAS], n = 49), involving patients who discontinued frontline second-generation (2G)\u2013tyrosine kinase inhibitors (TKIs) after sustaining deep molecular response for \u22652 years. Both trials successfully met their primary end points, with 12-month TFR rates of 76.5% and 55.1% in the NIL and DAS trials, respectively. No disease progression was observed, confirming the safety of this strategy. The 5-year treatment-free survival (TFS) rates were 68.6% and 50.9% for NIL- and DAS-treated patients, respectively. Although recurrent cases in both cohorts rapidly regained a molecular response, NIL-treated patients showed a more gradual molecular recurrence and a persistent gap between TFS and event-free survival, suggesting relatively stable immune surveillance. Comparative immune profiling, although exploratory, suggested an \u201cimmune paradox\u201d in the DAS cohort, characterized by expansion of effector memory T cells and mature CD57+ CD56dim natural killer cells alongside depletion of the \u201cimmune reservoir\u201d of na\u00efve and central memory cells. In the D-STOP trial, the retreatment group showed higher levels of effector regulatory T cells and exhausted CD4+ T cells compared with the TFR group. Furthermore, elevated prediscontinuation interleukin-1\u03b2 (IL-1\u03b2) and IL-6 levels were associated with molecular relapse. These findings suggest that 2G-TKI\u2013specific off-target effects influence TFR sustainability by modulating the immune microenvironment and the CD4+ helper cell status. The trials were registered at www.umin.ac.jp as UMIN000024984 (JALSG N-STOP216) and UMIN000024985 (JALSG D-STOP216).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020915","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:56:07Z","timestamp":1781812567000},"page":"6255-6267","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Treatment-free remission and immune profiling after frontline second-generation TKI therapy in CML"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"first","affiliation":[{"name":"1Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-0739","authenticated-orcid":false,"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[{"name":"2Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-7462","authenticated-orcid":false,"given":"Yuki","family":"Fujioka","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0112-6564","authenticated-orcid":false,"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"4Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan"},{"name":"5Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Kurata","sequence":"additional","affiliation":[{"name":"4Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-7432","authenticated-orcid":false,"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[{"name":"6Department of Transfusion and Cell Therapy, Hamamatsu University Hospital, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3369-7502","authenticated-orcid":false,"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5895-5382","authenticated-orcid":false,"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4059-1777","authenticated-orcid":false,"given":"Takeshi","family":"Maeda","sequence":"additional","affiliation":[{"name":"10Department of Hematology\/Oncology, Kurashiki Central Hospital, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Ozawa","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-1928","authenticated-orcid":false,"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[{"name":"13Blood Disorders Center, Aiiku Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-8806","authenticated-orcid":false,"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Institute of Science Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-1988","authenticated-orcid":false,"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[{"name":"15Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan"},{"name":"16Department of Medicine and Biosystemic Science, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-9498","authenticated-orcid":false,"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"17Department of Hematology and Oncology, Graduate School of Medicine, Nagoya University, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Unit for Radiation Effects on Humans, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2818-4270","authenticated-orcid":false,"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"19Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka Sakai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"4","key":"2026092210531243000_bib1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12185-008-0186-0","article-title":"Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH","volume":"88","author":"Kizaki","year":"2008","journal-title":"Int J Hematol"},{"issue":"5","key":"2026092210531243000_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","article-title":"Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system","volume":"35","author":"Tauchi","year":"2011","journal-title":"Leuk Res"},{"issue":"24","key":"2026092210531243000_bib3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026092210531243000_bib4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the new TARGET system","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int J Hematol"},{"issue":"11","key":"2026092210531243000_bib5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026092210531243000_bib6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2026092210531243000_bib7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"2026092210531243000_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026092210531243000_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","article-title":"Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)","volume":"24","author":"Fujisawa","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"2026092210531243000_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","article-title":"Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study","volume":"107","author":"Takahashi","year":"2018","journal-title":"Int J Hematol"},{"issue":"6","key":"2026092210531243000_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"16","key":"2026092210531243000_bib12","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European Stop Tyrosine Kinase Inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026092210531243000_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12185-026-04184-4","article-title":"Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan","volume":"124","author":"Takahashi","year":"2026","journal-title":"Int J Hematol"},{"issue":"2","key":"2026092210531243000_bib14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"2026092210531243000_bib15","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026092210531243000_bib16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2026092210531243000_bib17","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2026092210531243000_bib18","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026092210531243000_bib19","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2026092210531243000_bib20","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026092210531243000_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00262-025-04256-0","article-title":"Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients","volume":"75","author":"Cayssials","year":"2025","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2026092210531243000_bib22","doi-asserted-by":"crossref","first-page":"e20191009","DOI":"10.1084\/jem.20191009","article-title":"Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells","volume":"217","author":"Tanaka","year":"2020","journal-title":"J Exp Med"},{"issue":"20","key":"2026092210531243000_bib23","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/bloodadvances.2024012655","article-title":"Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study","volume":"8","author":"Matsumura","year":"2024","journal-title":"Blood Adv"},{"issue":"23","key":"2026092210531243000_bib24","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.3390\/cancers13235904","article-title":"Regulatory T cell as a biomarker of treatment-free remission in patients with chronic myeloid leukemia","volume":"13","author":"Fujioka","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2026092210531243000_bib25","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.18883","article-title":"Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: final 5-year analysis of DASFREE","volume":"202","author":"Shah","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"2026092210531243000_bib26","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2022.282005","article-title":"Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia","volume":"108","author":"Harrington","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"2026092210531243000_bib27","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1002\/cam4.925","article-title":"Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes","volume":"5","author":"Iriyama","year":"2016","journal-title":"Cancer Med"},{"issue":"10","key":"2026092210531243000_bib28","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation","volume":"25","author":"Kreutzman","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"2026092210531243000_bib29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cas.14692","article-title":"Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment","volume":"112","author":"Ishiyama","year":"2021","journal-title":"Cancer Sci"},{"issue":"8","key":"2026092210531243000_bib30","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2026092210531243000_bib31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24096","article-title":"Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2026092210531243000_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cas.13430","article-title":"Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation","volume":"109","author":"Kumagai","year":"2018","journal-title":"Cancer Sci"},{"issue":"7","key":"2026092210531243000_bib33","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026092210531243000_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"issue":"9","key":"2026092210531243000_bib35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ni1496","article-title":"Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol"},{"key":"2026092210531243000_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2017.08.004","article-title":"Interleukin-8 in cancer pathogenesis, treatment and follow-up","volume":"60","author":"Alfaro","year":"2017","journal-title":"Cancer Treat Rev"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6255\/2589203\/blooda_adv-2026-020915-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6255\/2589203\/blooda_adv-2026-020915-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:53:23Z","timestamp":1790088803000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6255\/569212\/Treatment-free-remission-and-immune-profiling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020915","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,14]]}}}